Ashley A. Merlino
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, RNA modifications and cancer, Lung Cancer Research Studies, Immune cells in cancer
Most-Cited Works
- → CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation(2017)756 cited
- → Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids(2017)559 cited
- → Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS(2018)71 cited
- → Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer(2018)67 cited
- → Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma(2017)34 cited
- → Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy(2022)23 cited
- → Abstract 52: CRISPR-mediated knock-out of A20 lowers the activation threshold and induces metabolic rewiring of CAR-T cells(2024)1 cited
- → S-Figure-1 from Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma(2023)
- → Data from Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma(2023)